Effect of Dehydration on Sleep Quality, Cognitive Skills, and Electromyographic Responses in Combat Athletes
NCT07118904, Not applicable, Completed, Abant Izzet Baysal University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effect of Dehydration on Sleep Quality, Cognitive Skills, and Electromyographic Responses in Combat Athletes | ClinicalTrials.gov |
| NCT number | NCT07118904 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 12 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Abant Izzet Baysal University | ClinicalTrials.gov |
| Conditions | Dehydration, Weight Loss, Weight Cycling, Sleep | ClinicalTrials.gov |
| Interventions | Rapid weight loss through dehydration | ClinicalTrials.gov |
| First posted | 2025-08-12 | ClinicalTrials.gov |
| Last updated | 2026-10-16 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Sleep monitoring and Evaluation | First trial monitoring, following one week Second trial monitoring and following one week Third trial monitoring (Due to randomized counterbalanced crossover design, monitoring will be performed three times, two as experimental and one as control). | Participants' sleep assessments will be conducted with a sleep monitor, which uses impulse radio ultra-wide band (IR-UWB) radar and Doppler technology, and has been shown to provide measurements as accurate and reliable as the polysomnography device, which is considered the gold standard in sleep assessment. Total sleep and wake times and durations of the sleep phases will be obtained in minutes from the recordings of the device. | ClinicalTrials.gov |
| Primary | Isokinetic Leg Strength Measurement | First trial testing, following one week Second trial testing and following one week Third trial testing (Due to randomized counterbalanced crossover design, testing will be performed three times, two as experimental and one as control). | Isokinetic leg strength measurements will be made with the Cybex Norm device. Peak torque data obtained during the measurements will be recorded and used in data processing. | ClinicalTrials.gov |
| Primary | EMG Measurements | First trial testing, following one week Second trial testing and following one week Third trial testing (Due to randomized counterbalanced crossover design, testing will be performed three times, two as experimental and one as control). | Electrical potentials of muscle cells are recorded with electromyography (EMG) and the activities of skeletal muscles are evaluated based on changes in these potentials. EMG measurement provides information about the muscles and motor nerves involved by analyzing motor unit action potentials. | ClinicalTrials.gov |
| Primary | Stroop test | First trial testing, following one week Second trial testing and following one week Third trial testing (Due to randomized counterbalanced crossover design, testing will be performed three times, two as experimental and one as control). | The Stroop test is a test that reflects frontal lobe region activity. | ClinicalTrials.gov |
| Primary | Symbol Digit Modalities Test | First trial testing, following one week Second trial testing and following one week Third trial testing (Due to randomized counterbalanced crossover design, testing will be performed three times, two as experimental and one as control). | The Symbol Digit Modalities Test is a test that evaluates complex visual spatial scanning, sustained attention and concentration, information processing speed and working memory. | ClinicalTrials.gov |
| Primary | Montreal Cognitive Assessment | First trial testing, following one week Second trial testing and following one week Third trial testing (Due to randomized counterbalanced crossover design, testing will be performed three times, two as experimental and one as control). | The Montreal Cognitive Assessment test evaluates cognitive functions such as attention and concentration, executive functions, memory, language, visual construction skills, calculation and orientation. The test scores range from 0 to 30, with a cut-off score of 21. Scores of 21 and above are considered normal. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)